Evogene
EVGN
15 hedge funds and large institutions have $66.8M invested in Evogene in 2014 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 3 closing their positions.
0.01% less ownership
Funds ownership: 1.65% → 1.64% (-0.01%)
16% less capital invested
Capital invested by funds: $79.8M → $66.8M (-$13.1M)
17% less funds holding
Funds holding: 18 → 15 (-3)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$1.69M |
| 2 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$535K |
| 3 |
Citigroup
New York
|
+$46.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
-$1.51M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$655K |
| 3 |
JP Morgan Chase
New York
|
-$622K |
| 4 |
Jane Street
New York
|
-$547K |
| 5 |
Goldman Sachs
New York
|
-$477K |
EVGN Hedge Fund Activity: Q2 2014 in Review
15 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q2 2014, worth a combined $66.8M — down 16% from $79.8M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of EVGN and 0 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 3 added.
The largest buyer was Waddell & Reed Financial, adding an estimated $1.69M. The largest seller was LMR Partners, exiting entirely with an estimated $1.51M sold.
- 15 institutional investors held Evogene (EVGN) as of Q2 2014, down from 18 in Q1 2014.
- Funds reported $66.8M of Evogene stock for Q2 2014, down 16% quarter-over-quarter.
- 0 funds opened new Evogene positions in Q2 2014 and 3 closed out, a net change of -3 holders.
- The largest Evogene buyer in Q2 2014 was Waddell & Reed Financial, an estimated $1.69M added.
- The largest Evogene seller in Q2 2014 was LMR Partners, an estimated $1.51M sold.
Based on aggregated 13F filings for Q2 2014.